Trending at Lumira Ventures

BioTheryX Receives IND Clearance from FDA to Proceed with Phase 1 Study of BTX-1188, a Molecular Glue, for the Treatment of Hematologic and Solid Malignancies

Alyssia Watkin Lumira News, Portfolio News, BioTheryX

Enrollment for Phase 1 Clinical Trial to Commence by End of 2021 BioTheryX, Inc., a clinical-stage company focused on targeted protein degradation to create life-saving medicines, today announced that the U.S. Food and Drug Administration (FDA) cleared the company to …

GenEp Raises $1.45 Million Seed Financing

Alyssia Watkin Portfolio News, GenEp

GenEp, Inc., a biotechnology company developing therapies that address unmet needs in patients with epilepsy, announced today the closing of a $1.45 million seed financing. The financing was co-led by the UVA Licensing & Ventures Group Seed Fund, Angelini Lumira …

Iterion Therapeutics Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint in Acute Myeloid Leukemia

Alyssia Watkin Portfolio News, Iterion Therapeutics

Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the initiation of a Phase 1 clinical trial to investigate tegavivint as a potential treatment for acute myeloid leukemia (AML). This investigator-initiated trial is being led …